Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (Nasdaq: SILO) reported that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders.
According to Silo Pharma, the Canadian application, licensed exclusively from Columbia University, covers methods to prevent or delay stress-induced fear and depressive-like behavior and enhance stress resilience. Corresponding IP has been granted or is progressing in multiple international markets, including a recently granted European patent. The company intends to pursue the FDA’s streamlined 505(b)(2) pathway for SPC-15 and highlights a broader pipeline in CNS and pain, alongside its managed AI agent subsidiary, QwikAgents.
Silo Pharma (Nasdaq: SILO) announced that the European Patent Office has granted European Patent No. EP3952852, covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain therapy targeting PTSD and stress-induced affective disorders. Silo holds an exclusive European license to this patent from Columbia University.
The patent protects methods of using selected serotonin 4 (5-HT4) receptor agonists to prevent stress-induced fear, depressive-like behavior, and related disorders when administered ahead of extreme stress exposure. According to Silo Pharma, this grant expands SPC-15’s intellectual property portfolio, complements protection granted and pending in five other major global markets, and supports its exclusive global license to develop, manufacture, and commercialize SPC-15.
Silo Pharma (Nasdaq: SILO) announced that its wholly owned AI subsidiary QwikAgents has engaged Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, to design and build a new AWS-native QwikAgents platform.
According to Silo Pharma, Caylent will create a fresh AWS-native foundation rather than migrate the existing application, preserving QwikAgents’ core functionality while enhancing scalability, performance and security for enterprise deployment and future product innovation. The engagement is structured to align with AWS funding programs, with funding support expected from AWS and Caylent. Silo highlights this collaboration as a key step in positioning QwikAgents for enterprise growth and in supporting the long-term commercialization strategy alongside its biopharmaceutical pipeline targeting PTSD, fibromyalgia, chronic pain and Alzheimer’s disease.
Silo Pharma (Nasdaq: SILO) reported progress across its two main growth platforms: commercialization of its QwikAgents enterprise AI-agent business and development of its lead PTSD therapeutic candidate, SPC-15. QwikAgents is completing final enhancements and infrastructure updates ahead of an anticipated commercial launch within the next 90 days, which management expects will begin generating initial revenue.
For SPC-15, an intranasal serotonin 5-HT4 receptor agonist for PTSD and anxiety, Silo is adding patent filings to broaden protection for formulation, delivery technology, and long-term commercial potential. The company expects to finish a drug-device robustness study of its microchip-based nasal spray within about 60 days, supporting an FDA Type C meeting request and a planned IND submission. Management also highlighted capital from a recently announced private placement to pursue these opportunities.
Silo Pharma (Nasdaq: SILO) announced that its wholly owned subsidiary QwikAgents has been accepted into Advanced Micro Devices’ AMD AI Developer Program. According to Silo Pharma, QwikAgents will gain access to AMD Developer Cloud credits, advanced AI tools, training resources and a global developer community to accelerate enterprise AI agent development.
QwikAgents is building a subscription-based AI agent platform, with starter plans from $14 per month, designed for individuals, developers, small businesses and enterprises. The platform targets use cases such as research, content creation, scheduling, coding, browser and workflow automation, and aims to leverage AMD resources for development, hosting, testing, optimization and potential training of AI workloads.
Silo Pharma (Nasdaq: SILO) entered definitive agreements for a private placement of 619,965 common shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to purchase up to an additional 1,239,930 shares in total, at $6.452 per share and associated warrants.
The upfront aggregate gross proceeds are expected to be approximately $4 million, before fees, with up to approximately $7.7 million in potential additional gross proceeds if all warrants are exercised in cash at an exercise price of $6.21 per share. The offering, led by H.C. Wainwright & Co. as exclusive placement agent, is expected to close on or about July 10, 2026, subject to customary conditions. According to Silo Pharma, net proceeds will be used for working capital and general corporate purposes, and the securities are being issued in a private placement under Section 4(a)(2) and Regulation D, with resale registration statements to be filed for the unregistered securities.
Silo Pharma (Nasdaq:SILO) announced that its wholly owned subsidiary QwikAgents has joined the NVIDIA Developer Program to support development of its enterprise AI agent integration platform.
QwikAgents aims to use NVIDIA’s AI software ecosystem, frameworks, and training resources to enhance autonomous AI workflows for business customers.
Silo Pharma (Nasdaq: SILO) engaged drug-device partner Resyca to run a robustness study on the microchip-based Soft-Mist nasal spray delivering SPC-15, its lead intranasal prophylactic PTSD treatment.
The 30-day study will test device performance and SPC-15 formulation stability and is expected to support a planned FDA Type C meeting and IND/Phase 1 strategy under a previously aligned 505(b)(2) pathway.
Silo Pharma (Nasdaq:SILO) reported positive stability data for its investigational PTSD prophylactic treatment SPC-15, a soft-mist intranasal formulation. Real-time data over nine months and six-month accelerated testing showed physical, chemical and microbiological stability within predefined specifications, supporting IND-enabling CMC requirements and advancement toward a first-in-human Phase 1 clinical trial.
Silo Pharma (Nasdaq: SILO) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) as of June 17, 2026. The stock will continue trading on the Nasdaq Capital Market, and the compliance matter is considered closed.
The company also highlighted confidence in advancing its lead PTSD candidate SPC-15 toward first-in-human trials and progressing its QwikAgents AI agents platform.